Therapy Induced Evolution Of Human Lung Cancer Revealed By Single Cell

When exploring therapy induced evolution of human lung cancer revealed by single cell, it's essential to consider various aspects and implications. Therapy-Induced Evolution of Human Lung Cancer Revealed by Single-Cell .... Biological features revealed by scRNA-seq were biomarkers of clinical outcomes in independent cohorts. This study highlights how therapy-induced adaptation of the multi-cellular ecosystem of metastatic cancer shapes clinical outcomes. Building on this, single-cell RNA sequencing (scRNA-seq) of metastatic lung cancer was performed using 49 clinical biopsies obtained from 30 patients before and during targeted therapy. Additionally, analysis of metastatic lung cancer biopsies before and after targeted therapy reveals molecular and immune adaptations that shape clinical outcomes. It's important to note that, heterogeneity and targeted therapy-induced adaptations in lung cancer ....

Similarly, navigating the landscape of EGFR TKI resistance in - Nature. EGFR tyrosine kinase inhibitors (TKIs) have revolutionized the management of EGFR -mutant non-small-cell lung cancer (NSCLC); however, resistance to these agents is inevitable in most patients ... Multimodal spatial-omics reveal co-evolution of alveolar progenitors .... In this context, the co-evolution of different cell subsets in the progression of precursor lesions to lung adenocarcinoma (LUAD) is incompletely understood. We generated spatial transcriptomic maps of 56 human precursor lesions and LUADs from 25 patients and of an independent cohort of 36 lesions from 19 patients, analyzing a total of 486,519 spots and 5.4 million cells.

We identify region-specific programs ... Furthermore, characterization of the tumor microenvironment by single-cell RNA .... With their paper “ Tumor microenvironment remodeling after neoadjuvant immunotherapy in non-small cell lung cancer revealed by single-cell RNA sequencing ” Hu et al.

(32) presented a unique description of TME alterations induced by combined neo-adjuvant CTx and PD-1 inhibition in early-stage NSCLC. Lung Cancer: Targeted Therapy in 2025 - PMC. Lung cancer treatment has changed in the last twenty years since the discovery of EGFR mutations. In this article, we will review the current state of the art for non-small cell lung cancer (NSCLC) actionable genomic alterations (AGA).

This perspective suggests that, antibody–drug conjugates in cancer therapy: current landscape .... Antibody-drug conjugates (ADCs) have emerged as a transformative modality in oncology by combining the target specificity of antibodies with the high potency of diverse cytotoxic payloads. Moreover, this review provides an integrative overview of ADCs, spanning from molecular design to clinical translation. Additionally, we dissect the structural components, antibodies, linkers, and payloads, and elucidate their ...